Mazdutide 5mg/vial Effectively Improve Metabolic Health And Manage Weight

Mazdutide 5mg/bottle core introduction

Research-grade triple receptor agonist peptide | Made in China, the world's first GCGR/GLP-1R/GIPR triple agonist, 5mg/vial

Common name : Mazdutide (IBI362)

Research and development code : IBI362

Structural type : Long-acting fusion peptide based on natural OXM sequence optimization

Targets : Glucagon receptor (GCGR) + glucagon-like peptide-1 receptor (GLP-1R) + glucose-dependent insulinotropic peptide receptor (GIPR)

Molecular weight : Approximately 4112.5 Da

Purity : ≥99.0% (UPLC test)

Appearance : White lyophilized powder

Storage : Store frozen at -20℃ away from light. After thawing, refrigerate at 2-8℃. Avoid repeated freeze-thaw cycles.

Core advantages and functions

the world's first GLP-1R/GCGR/GIPR triple agonist independently developed in China to enter the clinical development stage , representing a new generation of breakthrough treatment options in the field of metabolic diseases . By simultaneously activating three key metabolic receptors at the single-molecule level , it achieves comprehensive and synergistic regulation of energy metabolism, glucose homeostasis, and lipid metabolism . In preclinical and clinical studies of obesity, type 2 diabetes, and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, it has demonstrated superior weight loss and metabolic improvement efficacy compared to existing single-target GLP-1 drugs , making it a leading tool for metabolic disease mechanism research and new drug development .

✅Triple synergistic mechanism :

GLP-1R Excitement :

Powerful blood sugar lowering effect : It promotes insulin secretion in a glucose-dependent manner, improves β-cell function, and inhibits glucagon.

Central appetite suppression : Acts on the hypothalamus to produce a sustained feeling of fullness and reduce calorie intake.

Delaying gastric emptying : further increases satiety and slows down nutrient absorption.

GCGR Excitement :

Significantly increases energy expenditure : activates liver metabolism, increases basal metabolic rate, and achieves "active fat burning".

Targeted reduction of intrahepatic fat : Promotes fatty acid oxidation in the liver, specifically improves hepatic steatosis, and brings new hope for the treatment of NASH.

Improves blood lipid profile : Regulates lipoprotein metabolism and lowers triglycerides.

GIPR excited :

Enhances the browning of white adipose tissue : promotes thermogenesis in white adipose tissue and increases energy expenditure.

Synergistic improvement of insulin sensitivity : enhances the insulin-promoting effect of GLP-1 and improves insulin action in adipose tissue.

Potential central appetite regulation synergy : Synergistic with the GLP-1 pathway, it may further optimize the appetite suppression effect.

✅Original Chinese research and development advantages :

Innovative molecular design : Based on the natural OXM (gastrin) sequence , through site-directed amino acid substitution and C18 fatty acid side chain modification , the activity ratio of triple receptors and pharmacokinetic characteristics were precisely optimized, achieving long-term dosing once a week.

Leading CMC process :

High-efficiency biosynthesis : Using the Chinese hamster ovary (CHO) cell expression system , high-yield and high-stability recombinant production is achieved.

Proprietary purification process : Utilizing a multi-step chromatography combination (affinity, ion exchange, hydrophobic, molecular sieve) technology, both product-related impurities (such as polymers and fragments) and process-related impurities (host proteins and DNA) are rigorously removed.

Precise quality control : Advanced technologies such as reversed-phase UPLC, size exclusion chromatography, mass spectrometry, and circular dichroism spectroscopy are used to ensure purity ≥99.0%, monomer content ≥98.5%, correct advanced structure, and stable biological activity .

Comprehensive quality study :

Activity verification : The agonistic activity of cAMP on GLP-1R, GCGR and GIPR was verified by cell-based cAMP function experiments to ensure triple agonistic efficacy.

Consistency assurance : Provides complete quality comparability study data for active pharmaceutical ingredients (APIs) from early research and development to clinical use.

Clinical data support : Phase II clinical trials in China showed that Mazdutide was significantly better than dulaglutide in weight loss and blood sugar control in obese patients and patients with type 2 diabetes , demonstrating great therapeutic potential.

✅Product Features :

Triple target synergy : Single molecule covers three major metabolic pathways, resulting in synergistic therapeutic effects and enormous potential.

Powerful weight loss and blood sugar reduction : Preclinical and clinical data have confirmed its outstanding ability to reduce weight and improve metabolism.

Long-acting and convenient : The optimized long-acting design supports once-weekly subcutaneous administration, significantly improving research convenience and patient compliance.

Usage and Storage Guide

1. Reconstitution and preparation :

Special solvent :

The accompanying sterile reconstitution diluent (a buffer solution with a pH of approximately 7.4-8.0) must be used.

The use of unverified ordinary saline, water for injection, or other buffer solutions is strictly prohibited , as it may affect the solubility and stability of the long-acting peptide.

Standard preparation procedure :

Slowly inject 1.0 mL of the special diluent along the inner wall of the vial.

Gently rotate the vial horizontally in the palm of your hand for at least 2-3 minutes until a clear, colorless to slightly yellow solution is formed . Vigorous shaking, agitation, or vortexing is strictly prohibited to avoid generating bubbles or causing protein denaturation and aggregation.

5 mg/mL was obtained .

If dilution is required, please use the same dedicated diluent for secondary dilution and gently invert to mix.

Key points to note :

The preparation process should be carried out in a clean environment.

The reconstituted solution should be used within 1 hour .

Before administration , a visual inspection is required . The solution should be clear and free of visible particles, fibers, or discoloration .

2. Storage conditions :

Unreconstituted lyophilized powder :

Store frozen at -20℃ ± 5℃, away from light, and in its original packaging .

Under these conditions, the validity period is tentatively set at 24 months .

For long-term storage, it is recommended to store at -80℃ .

Reconstituted drug solution :

If not used immediately, it can be refrigerated at 2-8℃ for no more than 24 hours .

Do not freeze reconstituted solutions.

Transportation conditions :

Dry ice (-78℃) must be used for transportation to ensure a cold chain throughout the entire process.

The packaging should contain a temperature monitoring device.

3. Research and application plan :

Preclinical animal models :

Preferred model :

Diet-induced obesity (DIO) mice/rats : a core model for assessing comprehensive improvements in body weight, body composition, food intake, and energy expenditure .

Zucker diabetic obese (ZDF) rats or db/db mice : assess improvements in blood glucose, insulin, glycated hemoglobin, and insulin sensitivity .

Nonalcoholic steatohepatitis (NASH) models (such as choline-deficient high-fat diet, AMLN diet, STAM model): assess liver fat content, inflammation score, ballooning degeneration, and the reversal effect of fibrosis.

Dosage regimen :

Recommended route : subcutaneous injection .

Dosage reference (needs optimization based on specific model):

Low-dose group: 0.01 - 0.05 mg/kg

Medium dose group: 0.05 - 0.2 mg/kg

High-dose group: 0.2 - 1.0 mg/kg

Dosage frequency : Based on its long-acting characteristics, it can be designed to be administered once a week .

Monitoring and Evaluation :

Core endpoints : body weight, food intake, fasting blood glucose, and oral glucose tolerance test (OGTT).

Metabolic indicators : four blood lipid parameters, liver enzymes, liver triglyceride content, and insulin level.

Histopathology : Liver H&E staining, Sirius red staining (assessment of steatosis, inflammation, and fibrosis); white/brown adipose tissue analysis.

Energy metabolism : Indirect calorimetry is used to assess energy expenditure and respiratory quotient.

Mechanism of action study :

Receptor pharmacology : The affinity (KD) and selectivity for three targets were determined by radioligand binding assays or surface plasmon resonance techniques.

Signaling pathways : Investigate its ability to activate downstream signaling pathways such as cAMP/PKA and β-arrestin in different cell lines.

Central mechanism : The effects of this drug on hypothalamic feeding centers (such as ARC and PVN) and energy balance centers were investigated using techniques such as intraventricular administration, specific brain region lesioning, and c-Fos immunostaining.

Peripheral metabolism : Perform the hyperinsulin-positive glucose clamp test to accurately quantify insulin sensitivity throughout the body and in various tissues (liver, muscle, fat).

Molecular mechanisms : Transcriptomic and proteomic analyses of tissues such as liver and adipose tissue were performed to systematically reveal their regulatory networks.

4. Experimental Design Suggestions :

Control group setup :

Solvent control group

Single-target or multi-target positive control group (e.g., Semaglutide, Tirzepatide).

Dosage exploration requires setting up multiple dose groups to study the dose-response relationship.

Why choose Mazdutide, made in China?

A world-first innovative drug : Mazdutide is China's first-in-class original achievement in the field of metabolism . Choosing this product means standing at the forefront of scientific research in this field .

High clinical translational value : This product has been supported by a large amount of preclinical and clinical data . The research results can be quickly corroborated with clinical progress, and the translational potential is huge.

Technology is independent and controllable : From gene sequence design and cell line construction to large-scale production and quality control, we have complete independent intellectual property rights and full-chain technology .

Quality in line with international standards : Production processes and quality standards strictly follow international cGMP specifications , and data is complete and reliable, meeting high-level scientific research and application requirements.

Research and application directions

Cutting-edge research on metabolic diseases :

Explore the cross-dialogue and synergistic mechanisms among the three major pathways: GLP-1R, GCGR, and GIPR.

This study investigates the unique advantages and underlying mechanisms of triple stimulation in the treatment of NASH/NASH-related liver fibrosis.

To assess its long-term benefits for cardiovascular metabolic risk factors.

Benchmark Comparison for New Treatments :

As a benchmark molecule for the "triple stimulant" strategy, it is used to evaluate the merits of other similar drug candidates.

To explore the optimal dosage and dosing frequency, providing crucial evidence for subsequent clinical development.

Exploration of Precision Medicine :

To find biomarkers that can predict response to Mazdutide treatment.

To explore the differences in efficacy in patients with different metabolic phenotypes (e.g., predominantly hepatic steatosis vs. predominantly insulin resistance).

Preclinical/Clinical Data Reference

Preclinical : In the DIO model, Mazdutide showed superior weight loss effects compared to Semaglutide and Tirzepatide , and significantly reduced liver fat and improved insulin resistance.

Phase II clinical trial : In overweight/obese patients, Mazdutide 6 mg dose for 24 weeks resulted in significantly better mean percentage weight loss than dulaglutide , with a good safety profile.

Summarize

Mazdutide (IBI362), the world's first triple receptor agonist to enter clinical development , is not only an outstanding representative of original innovative drugs developed in China , but also a landmark in the new era of "multi-synergistic" approaches to metabolic disease treatment research . Its remarkable preclinical and clinical efficacy data bring revolutionary hope for conquering complex metabolic diseases such as obesity, diabetes, and NASH. Choosing Mazdutide manufactured in China will provide you with high-quality, highly active ingredients that meet international standards , helping you achieve leading research results in this cutting-edge field.

Need anything, please contact us

Hot Tags: mazdutide 5mg/vial effectively improve metabolic health and manage weight, China mazdutide 5mg/vial effectively improve metabolic health and manage weight manufacturers, suppliers, factory, AOD9604 Ideal For Competition Prep Peak Weeks, ace 031 1mg, buy aod 9604 pills, peptide cjc ipamorelin, Alternative to GHRP 6, hgh ipamorelin